Recovering a Derailed Clinical Trial – Best Practices
Partnerships sometimes do not work out as intended. For medium size and smaller biotech companies enlisting the services of a…
What’s Best for Your Phase III Clinical Study?
It’s worth your time to consider whether or not the commonly held belief that using a larger CRO for your…
Special Report: What’s in Store for Global Clinical Trials in 2022 and Beyond?
The Global Clinical Trials Market was valued at $44.3B USD in 2020, and by 2028 is expected to reach $69.3B…
Why Not Canada for Your Phase 3 Global Trial Expansion?
Pre-pandemic oncology was both the largest and fastest growing therapeutic area in the clinical trials market. A key market trend…
Diversity in Clinical Trial Participants: Canada Holds Promise
Participant diversity in clinical trials can be quite challenging to achieve. With COVID the concern about appropriate demographic representation is…
2020 a Year Like No Other: What it Takes to Keep Ahead of Rapid Change
This time last year none of us imagined we were about to go through a year like no other, and…
Overcome Oncology Clinical Trial Obstacles – 2020 Real World Evidence for 2021 and Beyond
Study start-up is one the most time-intensive areas within clinical drug development, accounting for two thirds or more of total…
Some Facts About Canada… Mitigate COVID-19 Impact on Your Clinical Trials
People often adhere to a myth and perpetuate it in answer to a difficult question, ending all further inquiry into…
Smaller CROs May Do It Better, Quicker – Especially in Times of Crisis
Pursuit of a path from discovery to drug approval as quickly as possible is a clear objective for most biotech…
Consider This Region for Your Phase 3 Global Trial
As of May 2020 ClinicalTrials.gov lists 16,150 oncology trials registered as Recruiting, Not yet Recruiting Studies, and the chart below…